Individualizing cancer care.
“The right drug for the right patient at the right time” has been the elusive and challenging quest of cancer researchers for decades. Genetic mutations, if correctly identified in time, are a beacon for early detection of disease and can be targeted by specific drugs. This is the key to successful therapy.
The LiquidBiopsy lab offers cutting edge circulating tumor cell (CTC) recovery and analysis services, providing physicians and oncology researchers real-time molecular information about their patients. This places the power of genomic testing within reach of every cancer patient, cancer survivor, and their doctors - all through a simple blood draw.